Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.3300 (3.49%) ($8.7500 - $9.3300) on Thu. Mar. 10, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.31% (three month average) | RSI | 55 | Latest Price | $9.3300(3.49%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 3% a day on average for past five trading days. | Weekly Trend | FOLD declines -0.3% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(63%) IWO(52%) IWC(49%) IWM(49%) XBI(46%) | Factors Impacting FOLD price | FOLD will decline at least -2.155% in a week (0% probabilities). VIXM(-28%) VXX(-13%) UUP(-12%) UNG(-8%) EDOC(-8%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.155% (StdDev 4.31%) | Hourly BBV | 1.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $8.5(9.76%) | 10 Day Moving Average | $8.36(11.6%) | 20 Day Moving Average | $8.63(8.11%) | To recent high | -25.1% | To recent low | 18.3% | Market Cap | $2.409b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |